Orthocell Posts Record U.S. Monthly Sales for Remplir Nerve Wrap
Australian medtech Orthocell recorded its strongest U.S. month for Remplir since launch, selling 92 units of the collagen nerve wrap in October 2026.
Australian medical device maker Orthocell Ltd reported its highest single-month U.S. sales total for its Remplir collagen nerve wrap since the product's commercial launch, with 92 units sold in October 2026, according to a company update.
Remplir is an FDA-cleared device engineered to support the repair and protection of peripheral nerves. Designed and manufactured in Australia, the wrap has been positioned by Orthocell as an emerging category leader in key international markets, reflecting a broader push by smaller medtech firms to capture share in nerve-repair segments traditionally dominated by larger players.
Read more Bahrain Awards Golden Licenses Worth $3.89B at Gulf Summit →
The October milestone signals accelerating commercial traction in the United States, a market that typically serves as a bellwether for global medical device adoption. Analysts covering the sector have noted that FDA clearance combined with consistent month-over-month volume growth can materially improve a device maker's valuation profile and attract distribution partnerships.
Orthocell's performance with Remplir underscores growing clinical and commercial interest in biologic-based nerve protection solutions, a niche that sits at the intersection of orthopedic surgery, plastic surgery, and peripheral nerve repair. The company designs and manufactures the device domestically in Australia before distributing to international markets.
Continue reading at All Financial Services & Investing.
